Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Sep 24, 2007

Array BioPharma Gets $40M Upfront in Cancer and Inflammation Partnership with Celgene

  • Celgene will make a $40 million upfront payment to Array BioPharma as part of a partnership focused on cancer and inflammation. Array stands to earn over $700 million more based on various milestones.

    Array will be responsible for all discovery and clinical development through Phase I or Phase IIa. Celgene has the option to select drugs developed under the collaboration that are directed to two of four mutually selected discovery targets. Celgene will then receive exclusive worldwide rights to those drugs, except for Array’s limited co-promotional rights in the U.S.

    Array also entitled to receive for each drug potential milestone payments of approximately $200 million if certain discovery, development, and regulatory milestones are achieved. An additional $300 million will be paid if certain commercial milestones are reached as well as royalties on net sales. Array will retain all rights to the other programs.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »